SRC and prostate cancer: Furthermore, treatment of prostate cancer cells with dasatinib, a Src and Bcr-Abl inhibitor, but not with docetaxel, resulted in reduced Y216GSK-3β phosphorylation as well as impaired cellular function in vitro and tumor growth in vivo.